Expert Review of Respiratory Medicine is a leading journal published by Taylor & Francis Ltd, dedicated to advancing the field of respiratory medicine through evidence-based research and comprehensive reviews. With a robust ISSN of 1747-6348 and an E-ISSN of 1747-6356, the journal disseminates essential insights into pulmonary and respiratory health, ranking an impressive #33 in Medicine - Pulmonary and Respiratory Medicine on Scopus, reflecting its significant contribution to this discipline. Established in 2007 and extending its reach through 2024, Expert Review of Respiratory Medicine serves as a crucial resource for professionals and researchers dedicated to improving respiratory health outcomes. Though not designated as an open-access journal, its impactful articles are pivotal in shaping clinical practices and guiding future research in respiratory medicine and related fields, including public health and immunology. By engaging with this journal, readers can stay abreast of the latest developments and critically evaluate advancements in respiratory care.

Welcome to the Canadian Journal of Respiratory Critical Care and Sleep Medicine, a prestigious peer-reviewed journal published by Taylor & Francis Inc. With an ISSN of 2474-5332 and an E-ISSN of 2474-5340, this journal serves as a vital platform for disseminating cutting-edge research in the fields of critical care, intensive care medicine, and pulmonary and respiratory medicine. Since its inception in 2017, the journal has established itself within the academic community, currently holding a Q2 ranking in Critical Care and Intensive Care Medicine and a Q3 ranking in Pulmonary and Respiratory Medicine for 2023. Although it operates under a standard access model, the journal remains committed to providing valuable insights and advancing knowledge through rigorous research articles, reviews, and case studies. Positioned in the heart of the United States, the journal aims to foster collaboration and innovation among healthcare professionals, researchers, and students dedicated to enhancing respiratory care and critical treatment protocols. Join us in exploring the dynamic intersection of research and practice that defines our mission.

Therapeutic Advances in Respiratory Disease is a prestigious open-access journal published by SAGE Publications Ltd, based in the United Kingdom. Since its inception in 2007, it has established itself as a leading platform for the dissemination of cutting-edge research in the fields of pulmonary and respiratory medicine and pharmacology. With an impressive impact factor and ranking—showing it is in the Q1 quartile in both Pharmacology (medical) and Pulmonary and Respiratory Medicine as of 2023—the journal's commitment to high-quality research is evident. In 2023, it ranks #32 out of 155 in Pulmonary and Respiratory Medicine and #57 out of 272 in Medical Pharmacology, positioning it in the 79th percentile across these disciplines. Open access since 2018, the journal ensures that its valuable content is readily accessible to a global audience of researchers, healthcare professionals, and students, facilitating the rapid exchange of knowledge that is crucial in the ever-evolving landscape of respiratory health. The journal's objectives include advancing understanding of respiratory diseases through innovative research and promoting the development of therapeutic strategies that improve patient outcomes, making it an essential resource for those dedicated to respiratory medicine.

THORAX is a premier academic journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine. Published by the esteemed BMJ Publishing Group in the United Kingdom, this journal has been a pivotal resource for researchers and clinicians since its inception in 1946. With a remarkable ranking of #6 out of 155 in its category, THORAX holds a prestigious position within the top 4% of its field, as indicated by its 2023 Q1 quartile classification and a strong Scopus ranking. The journal focuses on publishing high-quality research, reviews, and clinical studies that are essential for understanding respiratory diseases and their management. Although it is not an open-access journal, THORAX provides vital contributions to the academic community, fostering dialogue and innovation in pulmonary medicine. As it approaches its converged years, concluding in 2024, researchers, professionals, and students are encouraged to explore its rich repository of knowledge, while engaging with the most current advancements in the field.

Tuberculosis and Respiratory Diseases is a leading open-access journal published by THE KOREAN ACADEMY OF TUBERCULOSIS & RESPIRATORY DISEASES, dedicated to disseminating knowledge in the fields of infectious diseases and pulmonary medicine. Since its inception in 1980, the journal has undergone significant growth, currently recognized in the elite Q2 category for both Infectious Diseases and Pulmonary and Respiratory Medicine as of 2023. With an impact factor reflecting its esteemed position—ranked 52nd in its category—it serves as a vital resource for researchers and healthcare professionals seeking cutting-edge insights, studies, and advancements in the management and treatment of respiratory diseases, particularly tuberculosis. The journal is committed to providing open access to its content since 2013, ensuring that critical research is available to scholars worldwide, fostering collaboration and innovation in the global fight against respiratory illnesses.

BMJ Open Respiratory Research is a prestigious open access journal published by the BMJ Publishing Group, dedicated to advancing the field of pulmonary and respiratory medicine. Since its inception in 2014, the journal has provided a vital platform for the dissemination of innovative research and clinical findings, boasting an impressive Q1 ranking in its category as of 2023. With a Scopus rank of #35 out of 155 in Pulmonary and Respiratory Medicine, BMJ Open Respiratory Research is recognized for its high-quality content, engaging a global audience of researchers, healthcare professionals, and students. The journal embraces an open access model, ensuring that groundbreaking research is readily available to the community and stakeholders, thereby accelerating knowledge exchange and improving patient care. By focusing on diverse aspects of respiratory health, this journal plays a crucial role in shaping the future of respiratory research and practice.

Tuberkuloz ve Toraks (Tuberculosis and Thorax) is a distinguished journal published by the TURKISH ASSOCIATION OF TUBERCULOSIS AND THORAX located in Turkey. Serving as a pivotal platform for researchers and practitioners in the fields of Critical Care, Intensive Care Medicine, and Pulmonary and Respiratory Medicine, this journal has been disseminating vital research since 2003 and is committed to advancing knowledge and clinical practices related to tuberculosis and thoracic diseases. Although currently not an Open Access publication, its relevance is underscored by its rankings within Scopus, including a Q3 category in Critical Care and Intensive Care Medicine and a Q4 in Pulmonary and Respiratory Medicine, reflecting its significant contributions to the academic community. With a mission to foster the exchange of innovative ideas and encourage rigorous scholarly discourse, Tuberkuloz ve Toraks plays an essential role in addressing pressing health challenges associated with respiratory ailments and remains an invaluable resource for researchers, health professionals, and students dedicated to improving outcomes in thoracic health.

Pulmonary Medicine, published by HINDAWI LTD, stands as a prestigious open-access journal since 2010, dedicated to advancing the field of pulmonary and respiratory medicine. Located in Egypt, this journal is indexed with an ISSN of 2090-1836 and an E-ISSN of 2090-1844, and it has attained a commendable Q2 ranking in both the miscellaneous medicine and pulmonary health categories, indicative of its significant impact and quality. With an impressive Scopus ranking of #15 out of 155 in the pulmonary and respiratory medicine category, the journal is positioned in the 90th percentile, highlighting its relevance and contribution to ongoing research. The journal aims to publish high-quality original research, reviews, and clinical studies that address pressing issues in pulmonary health, making it a vital resource for researchers, clinicians, and students seeking to enhance their understanding and practice in respiratory medicine. By embracing an open-access model, Pulmonary Medicine provides a platform for disseminating knowledge, fostering collaboration, and driving innovation within the global scientific community.

COPD - Journal of Chronic Obstructive Pulmonary Disease is a premier peer-reviewed journal published by Taylor & Francis Inc. that focuses on the latest advancements in the understanding, diagnosis, and treatment of chronic obstructive pulmonary disease (COPD). As an Open Access journal since 2022, it enhances availability and dissemination of groundbreaking research, allowing researchers, healthcare professionals, and students to access vital information without barriers. The journal has established itself as a significant resource in pulmonary and respiratory medicine, boasting a commendable Q2 ranking in both medicine and specialty areas as of 2023, with an impressive Scopus rank of 66 out of 155. By bridging the gap between scientific exploration and clinical application, COPD aims to foster innovative approaches to managing this prevalent condition, making it an essential publication for those dedicated to improving patient care and advancing respiratory health.

LUNG is a prestigious academic journal that has been a cornerstone in the field of Pulmonary and Respiratory Medicine since its inception in 1959. Published by SPRINGER, the journal holds an impressive Q1 ranking in its category for 2023, reflecting its commitment to disseminating high-quality research and advancing clinical practices in respiratory health. With a Scopus rank of 24 out of 155 in its field, representing the top 16% of journals, LUNG continues to serve as a vital platform for researchers, clinicians, and students who are dedicated to addressing the complexities of lung diseases. Although currently not an open-access journal, LUNG offers valuable insights and significant contributions to the understanding of respiratory conditions, ensuring that its readership stays at the forefront of medical advancements. Researchers and professionals are encouraged to submit their work and engage with a thriving academic community that is passionate about improving patient outcomes in pulmonary health.